At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
Ritonavir +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial to Evaluate the Safety and Efficacy of Induction Treatment With Lamivudine Plus Stavudine Plus Abacavir Plus Amprenavir/Ritonavir Followed by Supervised Treatment Interruption in Subjects With Acute HIV Infection or Recent Seroconversion
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Oct 29, 2021
In Brief
A Phase 2 clinical trial evaluating Ritonavir, Abacavir sulfate, and 3 other interventions for HIV Infections. Completed, enrolled 121 participants across 18 sites.
Detailed Summary
This study will determine what effect taking a combination of five anti-HIV drugs during the early stage of HIV infection, then temporarily stopping them once or twice, may have on the amount of HIV virus in the blood (viral load). The study will also evaluate the safety and effectiveness of this anti-HIV drug combination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 1999
First PostedAug 2001
Study CompletionOct 2006
TodayJul 2026
First PostedAug 31, 2001
Enrollment StartMay 1, 1999
Study CompletionOct 1, 2006
TodayJul 2, 2026
Posted 24.8 years ago
Interventions
Ritonavirdrug
Abacavir sulfatedrug
Amprenavirdrug
Lamivudinedrug
Stavudinedrug